Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 43 articles:
HTML format
Text format



Single Articles


    April 2018
  1. DAVIS EJ, Johnson DB, Sosman JA, Chandra S, et al
    Melanoma: What do all the mutations mean?
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31345.
    PubMed     Text format     Abstract available


    March 2018
  2. TSAI KK, Bollin KB, Patel SP
    Obstacles to improving outcomes in the treatment of uveal melanoma.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31284.
    PubMed     Text format     Abstract available


  3. PRINTZ C
    First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
    Cancer. 2018;124:1097-1098.
    PubMed     Text format    


  4. LEHRER S, Rheinstein PH, Rosenzweig KE
    Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31262.
    PubMed     Text format    


  5. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31261.
    PubMed     Text format    


    October 2017
  6. MCWILLIAMS RR, Allred JB, Slostad JA, Katipamula R, et al
    NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31072.
    PubMed     Text format     Abstract available


  7. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31083.
    PubMed     Text format     Abstract available


  8. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    PubMed     Text format     Abstract available


    September 2017
  9. BENCI JL, Minn AJ, Vachani CC, Bach C, et al
    Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of care-plan use.
    Cancer. 2017 Sep 8. doi: 10.1002/cncr.30985.
    PubMed     Text format     Abstract available


    August 2017
  10. ROBIN TP, Jones BL, Gordon OM, Phan A, et al
    A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.
    Cancer. 2017;123:3040-3049.
    PubMed     Text format     Abstract available


    June 2017
  11. SZCZEPANIAK SLOANE RA, Gopalakrishnan V, Reddy SM, Zhang X, et al
    Interaction of molecular alterations with immune response in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  12. BYRNE EH, Fisher DE
    Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  13. WESTPHAL D, Glitza Oliva IC, Niessner H
    Molecular insights into melanoma brain metastases.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  14. LIM SY, Menzies AM, Rizos H
    Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  15. PEREZ-GUIJARRO E, Day CP, Merlino G, Zaidi MR, et al
    Genetically engineered mouse models of melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  16. REDDY BY, Miller DM, Tsao H
    Somatic driver mutations in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  17. BARUCH EN, Berg AL, Besser MJ, Schachter J, et al
    Adoptive T cell therapy: An overview of obstacles and opportunities.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  18. JOHNSON DB, Sullivan RJ, Menzies AM
    Immune checkpoint inhibitors in challenging populations.
    Cancer. 2017;123:1904-1911.
    PubMed     Text format     Abstract available


    May 2017
  19. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Text format     Abstract available


    March 2017
  20. KALINSKY K, Lee S, Rubin KM, Lawrence DP, et al
    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30663.
    PubMed     Text format     Abstract available


    February 2017

  21. Some Europeans with melanoma lack access to new, lifesaving drugs.
    Cancer. 2017;123:543-544.
    PubMed     Text format    


    December 2016
  22. HOU JY, Baptiste C, Hombalegowda RB, Tergas AI, et al
    Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30473.
    PubMed     Text format     Abstract available


  23. KIM DW, Haydu LE, Joon AY, Bassett RL Jr, et al
    Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.
    Cancer. 2016 Dec 2. doi: 10.1002/cncr.30463.
    PubMed     Text format     Abstract available


    October 2016
  24. CLARKE LE, Flake DD 2nd, Busam K, Cockerell C, et al
    An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
    Cancer. 2016 Oct 21. doi: 10.1002/cncr.30385.
    PubMed     Text format     Abstract available


    August 2016
  25. BHATIA S, Margolin K
    Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30260.
    PubMed     Text format    


  26. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    PubMed     Text format     Abstract available


  27. ALGAZI AP, Tsai KK, Shoushtari AN, Munhoz RR, et al
    Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-1L antibodies.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30258.
    PubMed     Text format     Abstract available


  28. JHAWAR SR, Kaufman HL, Goyal S
    Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Aug 6. doi: 10.1002/cncr.30244.
    PubMed     Text format    


  29. YU JB, Chiang VL
    Reply to timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Aug 6. doi: 10.1002/cncr.30243.
    PubMed     Text format    


    July 2016
  30. CURIEL-LEWANDROWSKI C, Swetter SM
    Lack of harms from community-based melanoma screening by primary care providers.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30194.
    PubMed     Text format    


  31. WEINSTOCK MA, Ferris LK, Saul MI, Geller AC, et al
    Downstream consequences of melanoma screening in a community practice setting: First results.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30177.
    PubMed     Text format     Abstract available


    June 2016
  32. QIAN JM, Yu JB, Kluger HM, Chiang VL, et al
    Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30138.
    PubMed     Text format     Abstract available


    April 2016
  33. PRINTZ C
    FDA approves new treatment of metastatic melanoma.
    Cancer. 2016;122:1149.
    PubMed     Text format    


    March 2016
  34. CHATTOPADHYAY C, Kim DW, Gombos DS, Oba J, et al
    Uveal melanoma: From diagnosis to treatment and the science in between.
    Cancer. 2016 Mar 15. doi: 10.1002/cncr.29727.
    PubMed     Text format     Abstract available


    February 2016
  35. TRICOLI JV, Blair DG, Anders CK, Bleyer A, et al
    Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.
    Cancer. 2016 Feb 5. doi: 10.1002/cncr.29871.
    PubMed     Text format     Abstract available


    October 2015
  36. STANG A, Jockel KH
    Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany.
    Cancer. 2015 Oct 19. doi: 10.1002/cncr.29755.
    PubMed     Text format     Abstract available


    August 2015
  37. WEISS SA, Hanniford D, Hernando E, Osman I, et al
    Revisiting determinants of prognosis in cutaneous melanoma.
    Cancer. 2015 Aug 26. doi: 10.1002/cncr.29634.
    PubMed     Text format     Abstract available


  38. BUCHBINDER EI, Sosman JA, Lawrence DP, McDermott DF, et al
    Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
    Cancer. 2015 Aug 11. doi: 10.1002/cncr.29622.
    PubMed     Text format     Abstract available


    July 2015
  39. MENZIES AM, Wilmott JS, Drummond M, Lo S, et al
    Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Cancer. 2015 Jul 28. doi: 10.1002/cncr.29586.
    PubMed     Text format     Abstract available


    June 2015
  40. PRINTZ C
    Coffee may lower risk of malignant melanoma.
    Cancer. 2015;121:1913.
    PubMed     Text format    


  41. LEHRER S
    Finasteride and dutasteride may reduce melanoma risk.
    Cancer. 2015 Jun 8. doi: 10.1002/cncr.29520.
    PubMed     Text format    


  42. LI WQ, Han J
    Reply to finasteride and dutasteride may reduce melanoma risk.
    Cancer. 2015 Jun 8. doi: 10.1002/cncr.29519.
    PubMed     Text format    


    May 2015
  43. ZHANG M, Qureshi AA, Fortner RT, Hankinson SE, et al
    Teenage acne and cancer risk in US women: A prospective cohort study.
    Cancer. 2015;121:1681-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: